Huang XJ, Zheng X, Wang K. Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B. World J Gastrointest Surg 2025; 17(10): 106414 [PMID: 41178887 DOI: 10.4240/wjgs.v17.i10.106414]
Corresponding Author of This Article
Xiao-Jing Huang, Department of Infection, Hangzhou Linping District First People’s Hospital, No. 369 Yingbin Road, Nanyuan Street, Linping District, Hangzhou 311100, Zhejiang Province, China. 13306521018@163.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Huang XJ, Zheng X, Wang K. Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B. World J Gastrointest Surg 2025; 17(10): 106414 [PMID: 41178887 DOI: 10.4240/wjgs.v17.i10.106414]
World J Gastrointest Surg. Oct 27, 2025; 17(10): 106414 Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.106414
Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B
Kai Wang, Xiao Zheng, Xiao-Jing Huang
Xiao-Jing Huang, Xiao Zheng, Kai Wang, Department of Infection, Hangzhou Linping District First People’s Hospital, Hangzhou 311100, Zhejiang Province, China
Author contributions: Huang XJ contributed to the conception and design, writing, review, and revision of the manuscript; all authors contributed to the analysis and interpretation of data, acquisition of data (acquired and managed patients), and final approved the manuscript.
Institutional review board statement: This study was approved by the Ethic Committee of Hangzhou Linping District First People’s Hospital.
Informed consent statement: Due to the retrospective and de-identified nature of this study, written informed consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Xiao-Jing Huang, Department of Infection, Hangzhou Linping District First People’s Hospital, No. 369 Yingbin Road, Nanyuan Street, Linping District, Hangzhou 311100, Zhejiang Province, China. 13306521018@163.com
Received: May 16, 2025 Revised: June 17, 2025 Accepted: August 22, 2025 Published online: October 27, 2025 Processing time: 160 Days and 22.9 Hours
Core Tip
Core Tip: By combining three serum biomarkers, hepatitis B core antibody, hepatitis B virus-DNA, and hepatitis B surface antigen, this study proposes a cost-effective, non-invasive diagnostic approach for assessing chronic hepatitis B-related liver fibrosis (LF) staging, providing advantages in operational convenience and repeatability. The multi-parameter model demonstrated superior diagnostic performance without compromising either sensitivity or specificity. Further, a strong correlation of hepatitis B core antibody and hepatitis B virus-DNA with LF progression was determined. Altogether, a promising non-invasive serological tool for LF staging is proposed in this study, providing a cost-effective solution to improve clinical diagnostics and patient care.
